Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSPPC-96 (Oncophage) vs Physician's Choice in Stage IV Melanoma
NCT00039000Phase 3Completed
- Sponsor
- Agenus Inc.
- Start
- Mar 2002
- Primary completion
- Dec 2005
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 9
01
Overview
Phase 3, randomised, open-label trial of vitespen in melanoma (2 arms), sponsored by Agenus Inc. Primary endpoint: Overall Survival. Started Mar 2002; status: completed.
02
Drugs
vitespen
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00039000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00039000.